The NCI-H522 cell line, also referred to as H522, is a human non-small cell lung cancer (NSCLC) cell line derived from a 57-year-old Caucasian male with lung adenocarcinoma. This cell line was established by the National Cancer Institute (NCI) and has been used as an in vitro model system for studying lung cancer biology, molecular mechanisms, and potential therapeutics.

Adenocarcinoma is the most common subtype of NSCLC and is frequently found in the outer parts of the lung. The NCI-H522 cell line is characterized as a bronchioloalveolar carcinoma, which is a subtype of lung adenocarcinoma that originates from the alveolar epithelium or bronchioles.

The NCI-H522 cell line has been employed in numerous studies to investigate various aspects of lung cancer biology, such as the role of oncogenes, tumor suppressor genes, and signaling pathways in cancer development and progression. Additionally, H522 cells have been used to test the efficacy of potential anti-cancer drugs, to study drug resistance mechanisms, and to investigate the tumor microenvironment in lung cancer.

In summary, the NCI-H522 cell line is a valuable model for researchers working in the field of lung cancer, providing insights into the molecular mechanisms underlying the disease and facilitating the development and testing of potential therapeutic strategies.